

# ALPHADIA IFA Anti-EmA (PUC) IgA Assay

IMMUNOFLUORESCENCE ASSAY  
FOR THE DETECTION  
OF ANTI - ENDOMYSIAL IgA  
ANTIBODIES IN HUMAN SERUM

UMBILICAL CORD

CAT # AD EMOU48      48 TESTS  
CAT # AD EMOU96      96 TESTS

FOR IN VITRO DIAGNOSTIC USE  
CONS : 2 - 8°C

## **ALPHADIA sa/nv**

DIAGNOSTIC PRODUCTS  
AVENUE VESALE 26 - B1300 WAVRE  
BELGIUM  
TEL : 32 (0) 10 24 26 49  
FAX : 32 (0) 10 24 55 99  
[contact@alphadia.be](mailto:contact@alphadia.be)

## INTRODUCTION

Indirect fluorescent assay (IFA) for anti-EmA IgA antibodies using umbilical cord as substrate has proven to be a good method to screen for Celiac disease. Endomysial antibodies of the IgA subclass (IgA EmA) react with the reticulin component of the endomysium of the smooth muscle in primate umbilical cord tissue. These antibodies can be found in 60-70% of patients with Dermatitis Herpetiformis (DH) on a non-restricted diet and in almost 100% of patients with Celiac disease (CD) and gluten-sensitivity enteropathy with partial or subtotalling villous atrophy. There is a small percentage of IgG EmA that will be negative IgA when screened. A negative result exhibited by a patient with overt clinical symptoms may need to be considered for IgG testing. It is recommended to perform an anti-Gliadin test in order to reach the maximum specificity of the test. It has been demonstrated that serum IgA endomysial antibodies were found in the majority (87%) of patients with untreated Celiac disease and approximately 70% of anti-Gliadin (IgA AGA) positive patients. The R1 anti-Reticulin (R1-ARA) appears to be a less reliable marker with less than 50% being positive. These findings were based on the same patient population. It should be noted that a strict adherence to a gluten-free diet will greatly effect the antibody results in most patients. IgA AGA and R1-ARA will normally disappear after one year while IgA EmA may persist at a lower titer. In this way the test may have prognostic value in monitoring strict adherence to diet.

## INTENDED USE

EmA/PUC IgA assay is a quantitative immunofluorescence test for the in vitro diagnostic detection of IgA antibody against endomysial antibodies in human serum. This test is designed for use as an aid in the diagnosis of Celiac Disease.

## PRINCIPLES

The primary test reaction involves circulating EmA IgA antibodies present in the patient's serum attach to their homologous EmA antigens. This occurs during the incubation period while the serum covers the umbilical cord antigen surface. A secondary reaction then follows a rinsing period that removes all unbound human antibody. The reagent used

in the secondary reaction is a fluorescein labeled anti-human IgA conjugate. The antigen surface is then thoroughly rinsed free of unbound conjugate and viewed under the appropriate fluorescent microscope for various morphological patterns of EmA fluorescence, which can be visually identified.

## KIT COMPONENTS

Primate Umbilical Cord substrate slide  
12 x 4 or 8 wells  
FITC Antihuman IgA conjugate w/Evans blue  
1 or 2 x 3 ml  
EmA IgA positive control : 1 x 1 ml  
Negative control : 1 x 1 ml  
Mounting medium : 1 x 3 ml  
PBS Buffer : 2 x 1 liter  
Blotters : 12 x 4 or 8 wells  
Coverslips (22 x 70 mm) : 1 x 12 each  
Note : liquid reagents contains the preservative Proclin 300 (< 0.1%).

## MATERIALS PROVIDED

1. FITC Conjugate No CAM2 (3 ml) is to be stored at 2-8°C upon receipt. The conjugate is stable at this temperature until expiration date on the vial. This reagent will react with the human IgA immunoglobulin class.
2. The antigen slides of monkey umbilicus sections No M1061U must be stored at 2-8°C or lower upon receipt. Check label for specific expiration date.
3. EmA positive control N° PCEA (1 ml) should be stored at 2-8°C upon receipt. Check label for specific expiration date.
4. Universal negative control N° NC (1 ml) should be stored at 2-8°C or lower upon receipt. Check label for specific expiration date.
5. Buffer pack N° PBS - Phosphate Buffered Saline is stable at room temperature storage for 5 years. The reconstituted buffer does not contain preservatives and should be stored at 2-8°C. Care should be taken to avoid contamination.
6. Mounting medium N° TMM3 is stable when stored at 2-8°C. Check label for specific expiration date.

Note : all kit components are available separately.

## MATERIALS REQUIRED BUT NOT PROVIDED

1. Micro-pipettor of 2-20µl range.

2. Timer (60 min range).
3. Graduated glass pipettes.
4. 1 L graduated cylinder.
5. Staining dish.
6. Moist chamber.
7. Clean containers for diluted buffers.
8. Distilled or deionized water.
9. Fluorescent microscope.
10. Lint free paper towel.

8. Use only distilled or deionized water and clean glassware.
9. Use separate pipette tips for each sample, control and reagent to avoid cross contamination.
10. Negative and positive controls must be run with each assay.
11. No assurance is given that these reagents are free of microbial or fungal contamination.
12. Incubation times and temperatures other than those specified may give erroneous results.

## PRECAUTIONS

1. **Caution** : all blood products should be treated as potentially infectious. Source human serum for the controls provided in this kit were found to be non-reactive for Hepatitis-B surface antigen (HbsAg) and Human Immunodeficiency Virus (HIV) 1 and 2 antibody when tested in accordance with tested in accordance with current FDA required tests. No known test methods can offer total assurance that products derived from human blood will not transmit HIV, Hepatitis or other potentially infectious agents. Therefore, these reagents and all patient's specimens should be handled at Biosafety Level 2 as recommended for any potentially infectious human serum or blood specimen in the CDC/NIH manual - Biosafety in Microbiology and Biomedical Laboratories - 1984 or latest edition.

2. For in vitro diagnostic use only.
3. Follow the procedural instructions exactly as they appear in this insert to insure valid results.
4. Handle slides by the edges since direct pressure on the antigen wells may damage the antigen.
5. Do not use reagents past their expiration date.
6. All reagents must be at room temperature (21-26 °C) before running the assay. Temperature will affect the results of the assay.
7. Once the procedure has started, do not allow the antigen in the wells, to dry out. This may result in false negative test results, or artefacts.

## STABILITY AND STORAGE

1. The kits should be stored at 2-8 °C.
2. Rehydrated PBS buffer remains stable for 60 days at 2-8 °C.

## SAMPLE COLLECTION

A whole blood sample should be collected by qualified personnel using approved aseptic venipuncture techniques. The samples may be stored at 2-8 °C if testing is to be done within 5 days. If stored longer, they should be frozen at -20 °C or lower. Do not use a frost-free freezer, which may allow the specimens to go through freeze-thaw cycles that may denature the IgA antibody and cause spurious results. Microbially contaminated, hyperlipemic, hemolytic, or heat treated samples should not be used. Clarify serum samples containing visible particulate matter by centrifugation.

## PREPARATION OF REAGENTS AND SAMPLES

1. Bring all reagents to room temperature before use.  
Remove the amount of slides to be used for the day's testing. Remove the slide from the foil pouch by tearing at notch. Carefully remove slide from the pouch and avoid touching the well areas. The slide is ready-to-use.
2. Prepare PBS buffer by pouring the contents

- of the package into a container and add deionized or distilled water to bring up to 1.0 liter final volume. Mix thoroughly. Store 1x solution at 2-8°C.
3. Positive and negative controls are ready-to-use. Do not dilute further.
  4. FITC conjugate is ready-to-use liquid. The conjugate is stable at 2-8°C until the labeled expiration date. The conjugate may be aliquoted into small amounts for extended storage and frozen (< -20°C) once.
  5. Patient's sera : Screening : dilute each patient serum 1:10 (1+9) with PBS. Prepare dilutions (10µl + 90µl) in test tubes.  
Titration : set up doubling dilutions of serum starting at 1:10 (i.e. 1:10, 1:40, 1:80, 1:160 etc)  
Mix all dilutions by vortexing on low speed.
  6. Assign each well of the slide the appropriate sample.

#### ASSAY PROCEDURE

**Screening** : dilute the sera 1:10 in PBS  
**Titration** : set up doubling dilutions of serum starting at 1:10, 1:20, 1:40, 1:80 etc.

1. Once slides reach room temperature tear slide envelope at notch. Carefully remove the slide and avoid touching the antigen areas. The slide is now ready to use.
2. Place a drop of diluted patient serum (20 to 30µl) and controls into the designated the antigen wells.
3. Place slide with patient's serum and controls in a moist chamber for 30 minutes at room temperature (approximately 24°C).
4. Remove slide from moisture chamber and tap the slide on its side onto a paper towel to allow the serum to run off. Using a wash bottle, gently rinse remaining sera from slide with distilled water being careful not to aim the rinse stream directly on to the well.
5. Soak in PBS for five minutes. Repeat an additional five minutes using fresh PBS.
6. Place a blotter on the lab table with absorbent side up. Remove slide from PBS and invert so that tissue side faces

- absorbent side of blotter. Line up wells to blotter holes. Place slide on top of blotter. Do not allow tissue to dry. Wipe back of slide with dry lint free paper towel. Apply sufficient pressure to slide while wiping to absorb buffer.
7. Deliver 1 drop (20-30µl) of conjugate per antigen well. Repeat steps 3-6.
  8. Place 4-5 drops of mounting medium on slide.
  9. Apply a 22 x 70 mm coverslip. Examine the slide under a fluorescent microscope. Note : to maintain fluorescence, store mounted slide in a moisture chamber placed in a dark refrigerator.

#### QUALITY CONTROL

1. Positive and negative serum controls must be included in each assay run to confirm reproducibility, sensitivity and specificity of the test procedure.
2. The negative serum control should result in little (+) or no fluorescence. If this control shows bright fluorescence, either the control, antigen, conjugate or technique may be at fault.
3. The positive serum control should result in bright 3+ to 4+ fluorescence. If this control shows little or no fluorescence, either the control, antigen, conjugate or technique may be at fault.
4. In addition to positive and negative serum controls, a PBS control should be run to establish that the conjugate is free from nonspecific staining of the antigen substrate. If the antigen shows bright fluorescence in the PBS control repeat using fresh conjugate. If the antigen still fluoresces, either the conjugate or antigen may be at fault.
5. If any of the controls do not meet the defined conditions, the run is invalid and patient results should not be reported.

#### INTERPRETATION OF RESULTS

**Positive** : A positive result is reported when staining of the endomysium connective tissue around the smooth muscle cells of vessels within the umbilical cord substrate displays a 1+ or greater fluorescence. Patients reactions should be compared with the positive control contained in the kit.

**Negative** A serum is considered negative for EmA if the fluorescence is less than 1+ at 1:10 dilution.

#### LIMITATIONS OF PROCEDURE

1. No diagnosis should be based on a single serologic test since various host factors must be taken into consideration.
2. The antibody titer obtained from individual samples do not necessarily correlate with disease severity and should not be reported as such. Antibodies from different patients may have different avidities. Paired sera run at the same time under the same conditions will give a better indication of the disease process.
3. The results obtained from this assay are intended to be an aid to diagnosis only. Each physician must interpret the results in light of the patient's history, physical findings and other diagnostic procedures. Low positive samples should be evaluated in light of clinical symptoms and results of testing for other autoimmune antibodies, such as gliadin IgG and IgA, tissue transglutaminase (tTG), or biopsy. Confirmation of results is advised by redrawing and retesting the patient.
4. Only if test instructions are rigidly followed will optimum results be achieved.
5. Use fresh serum or samples frozen only once and thawed. Samples that are improperly stored or are subjected to multiple freeze-thaw cycles may yield spurious results.

#### EXPECTED RESULTS

To evaluate the prevalence of IgA antibody to EmA/PUC and define a cut-off for the assay, one hundred four (104) serum specimens were obtained from healthy, asymptomatic blood donors ages 18 to 78 years from a blood bank in Northeast U.S. The sera samples were tested using the EmA/PUC IgA IFA test and the reference EmA (esophagus) IgA test. All of these 104 samples in this study were negative for anti-EmA IgA antibodies. Published studies performed in the U.S have found prevalence rates of antibody in the general population to be 1:250. Published studies have found celiac disease associated with a variety of other disease conditions. These conditions included a number of clinical manifestations affecting gastrointestinal, thyroid, hematopoietic, musculoskeletal, skin and mucous membranes, infertility, steoporosis/osteopenia and nervous system

disorders. The prevalence of celiac disease ranges from 1% to 29% in these conditions. A summary of CD prevalence in some of these disease conditions in children and adults includes anemia (8.5-29%), seizures and epilepsy (4.5-77%), hepatic disease (5.8%), diabetes (1-20%), thyroid disease (4.8-5.4%), and Down Syndrome (7.0%).

#### PERFORMANCE CHARACTERISTICS

##### Comparison

A study was performed using 286 patient samples obtained from a laboratory specializing in autoimmune diseases. These samples were assayed in the ALPHADIA EmA/PUC IgA IFA kit and the results compared to traditional monkey esophagus EmA IgA IFA kit. The results yielded 100% sensitivity, 99.3% specificity and 99.6% agreement to the reference procedure. The results are summarized as follows :

		Reference EmA IgA	
IFA		+	-
EmA/PUC	+	144	1
IgA IFA	-	0	141

Relative Sensitivity = 100% (C.I. 95% = 97.5 - 100%)  
Relative Specificity = 99.3% (C.I. 95% = 96.1 - 100%)  
Relative Agreement = 99.6% (C.I. 95% = 98.1 - 100%)

##### Cross reactivity

A study was performed using 50 autoimmune disease characterized samples obtained from an outside laboratory. The samples were run on the ALPHADIA EmA/PUC IgA IFA. No patients in this study exhibited a positive EmA/PUC IgA pattern on IFA. No cross reactivity was observed in the ALPHADIA EmA/PUC IgA Kit demonstrating that diseases such as SLE, myopathy, dermatitis, cirrhosis, polymyositis, etc., do not interfere with the assay.

##### Reproducibility

Studies were performed to demonstrate the intra-run, inter-day and inter-lot reproducibility of the ALPHADIA EmA/PUC IgA IFA test kit. The reproducibility studies were performed using the screening dilution of 1:10 for five sera; 4 positive sera samples (one high, one mid-range and two low) and one negative serum sample. The fluorescence intensities

were interpreted on a graded scale of 1+ to 4+. The intra-run study used the sera in replicates of 6 wells each. The same 5 samples were run on three lots of kits over 5 days for inter-day and inter-lot reproducibility. The negative sample remained negative in all wells throughout the testing period. All of the readings for the four positive sera demonstrated a consistent fluorescence intensity of 1+, 2+, 3+ and 4+ respectively.

#### BIBLIOGRAPHY:

1. Volta, U., Molinaro, N., DeFranceschi, L., Fratangelo, D., and Bianchi, F., *IgA Anti-Endomysial Antibodies on Human Umbilical Cord Tissue for Celiac Disease Screening*, Digestive Diseases and Sciences, Vol. 40, No. 9, pp. 1902-1905, 1995
2. Ladinsler, B., Rossipal, E., Pittschieler, K., *Endomysium Antibodies in Celiac Disease: An Improved Method*, Gut; 35: pp. 776-778, 1994
3. Reunala, T., Chorzelski, T.P., Viander, M., et al. *IgA anti-endomysial antibodies in dermatitis herpetiformis: correlation with jejunal morphology, gluten-free diet and anti-gliadin antibodies*. Br J Dermatol;117:185-91, 1987
4. Volta, U., Lenzi, M., Lazzari, R., et al. *Antibodies to gliadin detected by immunofluorescence and a micro-ELISA method; markers of active childhood and adult coeliac disease*. Gut: 26:667-71, 1985
5. Calabuig, M., Torregosa, R., Polo, P., et al. *Serological markers and celiac disease; a new diagnostic approach?*, J Pediatr Gastroenterol Nutr;10:435-42, 1990
6. Scott, H., Ek, J., Brandtzaeg, P., *Changes of serum antibody activities to various dietary antigens related to gluten withdrawal or challenge in children with coeliac disease*. Int Archs Allergy Appl Immunol;76:138-44, 1985
7. Volta, U., Molinaro, N., Fusconi, M. et al. *IgA Anti-endomysial Antibody Test A Step Forward in Celiac Disease Screening*. Dig. Diseases and Sci. Vol. 36, No 6, June 1991.
8. Kapuscinska, A., Zalewski, T., Chorzelski, T.P., et al. *Disease Specificity and Dynamics of Changes In IgA Class Anti-endomysial Antibodies in Celiac Disease*. J Pediatr Gastroenterol Nutr; 6:529-534, 1987
9. Not, T., Horvath, K., Hill, ID., Fasano, A., Hamed, A., Magazzu, G., *Endomysium antibodies in blood donors predicts a high prevalence of celiac disease in the USA*, Gastroenterology, 110 (4 Suppl):A1-1591, 1996
10. Pruessner, H., *Detecting Celiac Disease in Your Patients*, Amer. Fam. Physician, March 1, 1998
11. Catassi, C., *Screening of Celiac Disease*, Coeliac Disease, Proceedings of Seventh Intern'l Sympos. On Celiac Disease, Eds. Maki, M., Collin, P., Visakorpi, J., Univ. Tempere, 1997



ALPHADIA sa/nv  
DIAGNOSTIC PRODUCTS  
AVENUE VESALE 26 -  
B1300 WAVRE  
BELGIUM  
TEL : 32 (0) 10 24 26 49  
FAX : 32 (0) 10 24 55 99  
contact@alphadia.be

